Session » Vasculitis – Non-ANCA-Associated & Related Disorders Poster III: Giant Cell Arteritis

Date: Tuesday, November 12, 2019

Time: 9:00AM-11:00AM

Meeting: 2019 ACR/ARP Annual Meeting

9:00AM-11:00AM: Abstract Number: 2661

A Ten-Year Retrospective Review of Temporal Artery Biopsy Lengths in Alberta

9:00AM-11:00AM: Abstract Number: 2653

Adventitial Fibroblast, an Important Actor in Giant Cell Arteritis

9:00AM-11:00AM: Abstract Number: 2651

Are There Phenotypic Overlaps Between Giant Cell Arteritis Subgroups?

9:00AM-11:00AM: Abstract Number: 2648

Association Between Specimen Length and Number of Sections and Diagnostic Yield of Temporal Artery Biopsy: A Retrospective, Single Center Experience over a 21 Years’ Period

9:00AM-11:00AM: Abstract Number: 2676

Cardiovascular Treatment and the Incidence of Giant Cell Arteritis (GCA) – a Population-Based Case-Control Study

9:00AM-11:00AM: Abstract Number: 2665

Clinical Outcomes of Patients with Giant Cell Arteritis and Polymyalgia Rheumatica Symptoms Treated with Tocilizumab in Routine Clinical Practice

9:00AM-11:00AM: Abstract Number: 2674

Clinical Symptoms and Associated Vascular Imaging Findings in Takayasu’s Arteritis Compared to Giant Cell Arteritis

9:00AM-11:00AM: Abstract Number: 2687

Clinicopathologic Associations in a Large International Cohort of Patients with Giant Cell Arteritis

9:00AM-11:00AM: Abstract Number: 2664

Color Doppler Ultrasound for the Diagnosis of Giant Cell Arteritis in Montreal: A Canadian Single Center Experience

9:00AM-11:00AM: Abstract Number: 2652

Comparison Between Transmural and Isolated Periadventitial And/or Adventitial Inflammation at Temporal Artery Biopsy: A Single Center Cohort of Biopsy-Positive GCA with Long Term Follow-up

9:00AM-11:00AM: Abstract Number: 2654

Comparison of Aortitis and Non-Inflammatory Thoracic Aortic Aneurysms Undergoing Open Surgical Repair

9:00AM-11:00AM: Abstract Number: 2649

Comparison of Biopsy Proven Giant Cell Arteritis in North America and South Europe: A Population-Based Study

9:00AM-11:00AM: Abstract Number: 2688

Comparisons of Strategies for Diagnostic Assessment in Giant Cell Arteritis: Results from an International Observational Cohort

9:00AM-11:00AM: Abstract Number: 2692

Coronary Artery Disease in a Population-Based Cohort of Biopsy-Proven Giant Cell Arteritis in Southern Sweden

9:00AM-11:00AM: Abstract Number: 2666

Development and Outcome of Aortic Complications During Tocilizumab (TCZ) Treatment of GCA and Histopathologic Evidence of Residual Inflammation

9:00AM-11:00AM: Abstract Number: 2667

Efficacy and Safety of Tocilizumab in Giant Cell Arteritis: A Monocentric Real-life Experience

9:00AM-11:00AM: Abstract Number: 2682

Efficacy of Tocilizumab in Giant Cell Arteritis, Independent of the Time of Disease Evolution

9:00AM-11:00AM: Abstract Number: 2685

Factors Contributing to Capturing Positive Findings on Temporal Artery Biopsy: An Australian Experience from Two Rheumatology Referral Centers

9:00AM-11:00AM: Abstract Number: 2690

Fast Track Clinic (FTC) for Giant Cell Arteritis (GCA) – the United States Experience

9:00AM-11:00AM: Abstract Number: 2647

Flares and Long-term Remission in Large-vessel Giant Cell Arteritis in Northern Italy: Characteristics and Predictors in a Long-term Follow-up Study

9:00AM-11:00AM: Abstract Number: 2658

Giant Cell Arteritis Diagnostic Workup Among Medicare Beneficiaries

9:00AM-11:00AM: Abstract Number: 2670

Giant Cell Arteritis with Intracranial Vasculitis: A Case Series

9:00AM-11:00AM: Abstract Number: 2659

Giant-Cell Arteritis Associated with Myeloproliferative Neoplasms: A Retrospective Case–Control Study

9:00AM-11:00AM: Abstract Number: 2689

GM-CSF Pathway Signature Identified in Temporal Artery Biopsies of Patients with Giant Cell Arteritis

9:00AM-11:00AM: Abstract Number: 2677

Healthcare Resources Utilization in Giant Cell Arteritis – a Population-Based Study

9:00AM-11:00AM: Abstract Number: 2655

Large Vessel Vasculitis: Diagnosis Is Very Frequent with Ultrasound Examination and Shows Responsiveness to Treatment

9:00AM-11:00AM: Abstract Number: 2663

Maintained Benefit in Health-Related Quality of Life of Patients with Giant Cell Arteritis Treated with Tocilizumab Plus Prednisone Tapering: Results from the Open-Label, Long-Term Extension of a Phase 3 Randomized Controlled Trial

9:00AM-11:00AM: Abstract Number: 2680

Optimization of Tocilizumab Therapy in Giant Cell Arteritis: A Multicenter Real Life Study of 134 Patients

9:00AM-11:00AM: Abstract Number: 2671

PET/CT Vascular Findings at Baseline and Six Months in Patients with Newly Diagnosed Giant Cell Arteritis

9:00AM-11:00AM: Abstract Number: 2668

Pharmacokinetics and Pharmacodynamics of Tocilizumab in Combination with Prednisone Tapering in Patients with Giant Cell Arteritis: 3-Year Results from a Randomized Controlled Phase 3 Trial

9:00AM-11:00AM: Abstract Number: 2650

Predictors of Relapse in Giant Cell Arteritis: Data from an International Collaboration

9:00AM-11:00AM: Abstract Number: 2673

Presentation and Management of Giant Cell Arteritis in a Real-World Setting (Artemis Study)

9:00AM-11:00AM: Abstract Number: 2660

Rationalizing the Use of MRI of the Scalp Arteries in the Diagnosis of Giant Cell Arteritis Through Multivariable Predictive Modelling

9:00AM-11:00AM: Abstract Number: 2686

Real Life Data over 4 Years from a Fast Track GCA Pathway in Coventry

9:00AM-11:00AM: Abstract Number: 2684

Real-world Comparative Study of Methotrexate vs Tocilizumab in Patients with Giant Cell Arteritis with Large Vessel Involvement

9:00AM-11:00AM: Abstract Number: 2678

Response to Tocilizumab in Patients with Giant Cell Arteritis, According to Ischemic vs Systemic Symptoms

9:00AM-11:00AM: Abstract Number: 2675

Risk of Potential Glucocorticoid-Related Adverse Events in Patients with Giant Cell Arteritis: Results from a US-based Electronic Health Records Database

9:00AM-11:00AM: Abstract Number: 2646

Survival of Large Vessel Giant Cell Arteritis in Northern Italy During a 26-year Period : No Correlation with Demographical, Clinical, Laboratory and Imaging Data

9:00AM-11:00AM: Abstract Number: 2669

Survival Trends in Giant Cell Arteritis: A Population-based Cohort Study

9:00AM-11:00AM: Abstract Number: 2662

Temporal Artery Biopsy Lengths in Alberta: Which Surgical Subspecialty Achieves Optimal Biopsy Lengths?

9:00AM-11:00AM: Abstract Number: 2645

The Anteromedial Ultrasound Examination of the Large Supraaortic Vessels Identifies Higher Rates of Large Vessel Involvement Than Previous Reported in Patients with Giant Cell Arteritis

9:00AM-11:00AM: Abstract Number: 2657

The Association Between Bisphosphonates and Giant Cell Arteritis: A Retrospective Cohort Study

9:00AM-11:00AM: Abstract Number: 2656

The Veterans Health Administration (VHA) National Database Cohort: Incident Ophthalmic Complications in Giant Cell Arteritis (GCA) Patients with a Negative Temporal Artery Biopsy

9:00AM-11:00AM: Abstract Number: 2679

Tocilizumab in Giant Cell Arteritis: Route of Administration: Intravenous or Subcutaneous

9:00AM-11:00AM: Abstract Number: 2681

Tocilizumab in Giant Cell Arteritis: The Safest and Most Effective Initial Dose of Prednisone

9:00AM-11:00AM: Abstract Number: 2691

Treatment Patterns, Disease Burden and Outcomes in Patients with Giant Cell Arteritis and Polymyalgia Rheumatica

9:00AM-11:00AM: Abstract Number: 2672

Ultrasonography in the Diagnosis of Giant Cell Arteritis

9:00AM-11:00AM: Abstract Number: 2644

Ultrasound to Monitor Treatment Response in Large Vessel Giant Cell Arteritis

9:00AM-11:00AM: Abstract Number: 2683

Visual and Quantitative Assessment of Cranial Arteries on FDG-PET/CT Can Reliably Diagnose Cranial Giant Cell Arteritis

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].